Dob, Slovenia, May 16, 2023. Viewers can now watch MENAFLIX programming from the Middle East anywhere in the world on any device with internet access thanks to global content distribution provider, STN. Announced today on the first day of CABSAT, STN – one of the founding partners of MENAFLIX – now offers content owners, the… Read More »
24 January 2023 – The world’s premier digital cinema delivery network, Digital Cinema Distribution Coalition (DCDC), and KenCast, the developer of the leading digital cinema content delivery solution, have entered a new long-term agreement to ensure the flawless delivery of content across the U.S. KenCast technology supports DCDC’s delivery of feature, promotional, pre-show and live… Read More »
Microsoft has announced the expanded availability of its AccountGuard security service program to help healthcare organizations guard against cyber attacks from nation-states. WHY IT MATTERS The software giant is making AccountGuard available to a number of healthcare providers, including hospitals, care facilities, clinics, labs and clinicians, as well as pharmaceutical, life sciences and medical device companies… Read More »
Following its acquisition of the Kathrein rail antenna portfolio in May, HUBER+SUHNER has introduced an expanded connectivity offering for customers in the railway market. The complete documentation for all former Kathrein antennas is now available online, with existing customers able to access this in the same way as for HUBER+SUHNER antennas. Former Kathrein rail customers… Read More »
The study was conducted among 672 women under the age of 59 who received a drug called ribociclib, in combination with a common form of hormone therapy. Seventy percent of the women who took the combination therapy were alive after 42 months according to the findings, compared to 46% for women who were treated with… Read More »
SATURDAY, June 1, 2019 — Adding a newer drug to standard hormone therapy lengthens the lives of younger women with advanced breast cancer, a new trial has found. The drug, called Kisqali (ribociclib), is already approved for treating such patients — based on earlier results showing it can delay the progression of their cancer. This… Read More »